The GLP-1 nutritional support market holds a small yet expanding presence across multiple parent sectors
Why Retatrutide Has a Different Cost Profile Retatrutide is currently one of the more expensive research peptides per mg due to manufacturing complexity
We cover: Why chasing healthcare superintelligence misses the point How Color uses AI to speed up care and not take over decision-making Their pivot from genetic testing to full-scale clinical delivery How they cut time to treatment in half and boosted screening by 70% Partnering with OpenAI, Memorial Sloan Kettering, and major employers Tune in wherever you listen to podcasts
We have no clue how economic factors like tariffs could affect supply chains and price hikes, even for U.S.-formulated drugs (though Eli Lilly has been bracing for new tariffs on pharmaceuticals)
Sex differences in GLP-1 signaling across species
It belongs to a novel class of agents known as triple agonists, designed to simultaneously activate three distinct hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors